NovoCure (NVCR) Receivables (2014 - 2026)

NovoCure has disclosed Receivables across 13 years of filings, most recently posting $61.4 million for Q1 2026.

• Receivables for Q1 2026 came in at $61.4 million, up 51.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $61.4 million (up 51.15% YoY), and the FY2025 annual result was $66.5 million, up 62.93% from the prior year.
• Receivables came in at $61.4 million for Q1 2026 at NovoCure, down from $66.5 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $101.0 million in Q1 2022 to a low of $17.5 million in Q3 2022.
• The 5-year median for Receivables is $46.7 million (2025), against an average of $54.0 million.
• Across the five-year window, Receivables surged 443.65% in 2022 and plunged 65.03% in 2024, its largest moves.
• NovoCure's Receivables stood at $28.2 million in 2022, then surged by 132.57% to $65.5 million in 2023, then slumped by 37.7% to $40.8 million in 2024, then jumped by 62.93% to $66.5 million in 2025, then retreated by 7.64% to $61.4 million in 2026.
• The last three Receivables figures came in at $61.4 million (Q1 2026), $66.5 million (Q4 2025), and $46.7 million (Q3 2025), per Business Quant data.